Amphastar (AMPH) Q2 2026 Earnings Call Transcript

Amphastar reported Q2 net revenues of $183.9M (+5% YoY) and gross margin of 50.8% (up from 49.6%), supported by higher-margin launches like ipratropium bromide and stronger unit volumes. Operating cash flow was $51.3M and the company repurchased ~$45.0M of shares in Q2, while full-year sales growth guidance (mid-single digit to high-single digit) was maintained. The key overhang is IMS’ FDA warning letter, with expected additional expense of $2M–$3M per quarter for coming quarters and potential (though not expected) production shutdowns; insulin aspart remains on track for a 2027 commercial launch (subject to approval).

Analysis

The market should focus less on the headline growth rate and more on quality of earnings. Amphastar is showing that a better mix can offset legacy erosion, but the stock’s real sensitivity is to whether IMS remains a nuisance or becomes a true capacity/service problem. Because that site is roughly a third of revenue, even a modest deterioration in batch release speed can create hidden share loss before it shows up in reported sales; that is where competitors in injectables and rescue meds can quietly pick up shelf space over the next 1-2 quarters.

The 340B reset is the cleaner near-term earnings lever. This is a pricing-recapture story, not a volume story, so if the consultant is effective, gross margin can stay structurally higher even with remediation expense layered in. The key falsifier is another quarter of margin compression or evidence that the duplicate-discount fix stalls; that would imply the current profitability mix is less durable than management suggests.

Over 6-18 months, the stock is a tug-of-war between recurring buybacks/cash flow and binary regulatory risk. Consensus is likely over-discounting the warning letter while underappreciating that the insulin aspart program sounds economically ordinary rather than transformative; that makes it less of a multiple re-rate catalyst than investors may hope. If FDA interactions stay routine and no shutdown is signaled, AMPH can grind higher; if the agency forces line interruptions, the downside is sharper because customers in this category switch fast once supply confidence breaks.

Key Decisions for Investors

• Buy AMPH only on a post-earnings or post-news pullback of 5-10% if the market is extrapolating an IMS shutdown that has not been confirmed; 3-6 month upside is driven by margin mix and 340B recapture, with a hard stop if FDA language turns restrictive.
• Pair trade: long AMPH / short XPH for the next 1-3 months to isolate company-specific margin recovery versus a broader pharma basket that should not benefit from the 340B or launch mix tailwinds.
• Do not initiate aggressive options exposure until the FDA cadence becomes clearer; the binary risk is not direction but timing, and near-dated calls/puts are likely to decay if remediation remains procedural.
• If the next update shows no production interruption and gross margin stays near the current range, add on strength; if management cuts sales guidance or acknowledges any line shutdown, exit immediately because customer share loss could be a multi-quarter issue.